| Literature DB >> 32500431 |
Giammauro Berardi1, Marco Colasanti2, Giovanni Battista Levi Sandri2, Celeste Del Basso2, Stefano Ferretti2, Andrea Laurenzi2, Nicola Guglielmo2, Roberto Luca Meniconi2, Mario Antonini3, Gianpiero D'Offizi4, Giuseppe Maria Ettorre2.
Abstract
COVID-19 is rapidly spreading worldwide. Healthcare systems are struggling to properly allocate resources while ensuring cure for diseases outside of the infection. The aim of this study was to demonstrate how surgical activity was affected by the virus outbreak and show the changes in practice in a tertiary referral COVID-19 center. The official bulletins of the Italian National Institute for the Infectious Diseases "L. Spallanzani" were reviewed to retrieve the number of daily COVID-19 patients. Records of consecutive oncological and transplant procedures performed during the outbreak were reviewed. Patients with a high probability of postoperative intensive care unit (ICU) admission were considered as high risk and defined by an ASA score ≥ III and/or a Charlson Comorbidity Index (CCI) ≥ 6 and/or a Revised Cardiac Risk Index for Preoperative Risk (RCRI) ≥ 3. 72 patients were operated, including 12 (16.6%) liver and kidney transplantations. Patients had few comorbidities (26.3%), low ASA score (1.9 ± 0.5), CCI (3.7 ± 1.3), and RCRI (1.2 ± 0.6) and had overall a low risk of postoperative ICU admission. Few patients had liver cirrhosis (12.5%) or received preoperative systemic therapy (16.6%). 36 (50%) high-risk surgical procedures were performed, including major hepatectomies, pancreaticoduodenectomies, total gastrectomies, multivisceral resections, and transplantations. Despite this, only 15 patients (20.8%) were admitted to the ICU. Only oncologic cases and transplantations were performed during the COVID-19 outbreak. Careful selection of patients allowed to perform major cancer surgeries and transplantations without further stressing hospital resources, meanwhile minimizing collateral damage to patients.Entities:
Keywords: COVID-19; General surgery; Surgical oncology
Mesh:
Year: 2020 PMID: 32500431 PMCID: PMC7271142 DOI: 10.1007/s13304-020-00825-3
Source DB: PubMed Journal: Updates Surg ISSN: 2038-131X
Fig. 1Timeline of events in our hospital since Italian national lockdown
Characteristics of patients operated during the COVID-19 outbreak (March 9–April 24, 2020)
| Age (years) | 64 (53–74) |
| Gender F/M | 25/47 |
| Comorbidities | 19 (26.3%) |
| ASA score | 1.9 ± 0.5 |
| Charlson Comorbidity Index | 3.7 ± 1.3 |
| Revised Cardiac Risk Index for Preoperative risk | 1.2 ± 0.6 |
| Previous surgery | 21 (30.5%) |
| Cirrhosis | 9 (12.5%) |
| Neoadjuvant systemic therapy | 12 (16.6%) |
| High-risk patients | 16 (22.2%) |
| Diagnosis | |
| Colorectal cancer | 16 (22.2%) |
| Cholangiocarcinoma | 8 (11.1%) |
| Colorectal liver metastases | 13 (18.0%) |
| Hepatocellular carcinoma | 3 (4.1%) |
| Pancreatic ductal adenocarcinoma | 6 (8.3%) |
| Gastric cancer | 3 (4.1%) |
| Renal clear cell carcinoma | 4 (3.6%) |
| Sarcoma | 2 (5.5%) |
| Adrenal cancer | 1 (1.3%) |
| Gastrointestinal stromal tumor | 2 (5.5%) |
| Other malignancya | 2 (5.5%) |
| HCV related liver cirrhosis | 2 (5.5%) |
| HIV related liver cirrhosis | 1 (1.3%) |
| Alcohol related liver cirrhosis | 1 (1.3%) |
| NAFLD | 1 (1.3%) |
| Autoimmune hepatitis | 1 (1.3%) |
| Chronic kidney failure | 6 (8.3%) |
Data expressed as median and interquartile ranges or absolute count and percentages
ASA American Society of Anesthesiology, HCV hepatitis C virus, HIV human immunodeficiency virus, NAFLD non-alcoholic fatty liver disease
aOne liver cistoadenocarcinoma, one suspicious malignant abdominal lymph node
Type of surgical procedures and operative details of patients operated during the COVID-19 outbreak (March 9–April 24, 2020)
| High-risk surgical procedures | 36 (50.0%) |
| Type of surgical procedure | |
| Colorectal resectiona | 15 (20.8%) |
| Major hepatectomy w/o hepaticojejunostomy | 14 (19.4%) |
| Minor hepatectomy | 11 (15.2%) |
| Pancreaticoduodenectomy | 6 (8.3%) |
| Total gastrectomy | 1 (1.3%) |
| Distal gastrectomy | 2 (2.7%) |
| Nephrectomy | 2 (2.7%) |
| Multivisceral resection | 2 (2.7%) |
| Other malignant proceduresb | 7 (9.7%) |
| Orthotopic liver transplantationc | 6 (8.3%) |
| Kidney transplantation | 6 (8.3%) |
| Laparoscopic approach | 26 (36.1%) |
| Conversion | 0 (0%) |
| Blood loss (mL) | 400 (100–600) |
| Operative time (min) | 390 (200–400) |
| Patients admitted to the ICU | 15 (20.8%) |
ICU intensive care unit
aFour right colectomies, nine left colectomies, and two anterior rectal resections
bTwo gastric wedge resections, one nephrectomy with removal of inferior vena cava a right atrium tumor thrombus, one partial nephrectomy, one adrenalectomy, one transanal endoscopic mucosectomy, and one abdominal lymph node biopsy
cMELD score of patients at the time of liver transplantation: 28 (23–33)
Fig. 2Number of COVID-19 patients per day and general surgery cases since the hospitalization of the first COVID-19 patients
Characteristics of patients operated for malignancy according to the two phases of the COVID-19 outbreak
| Jan 31–Mar 8 2020, | Mar 9–April 24 | ||
|---|---|---|---|
| Age (years) | 64 (53–74) | 64 (53–77) | 0.38 |
| Gender F/M | 22/26 | 25/47 | 0.22 |
| Comorbidities | 29 (53.7%) | 6 (21.4%) | |
| ASA score | 2.3 ± 0.5 | 1.9 ± 0.5 | |
| Charlson Comorbidity Index | 5.1 ± 1.2 | 3.7 ± 1.3 | |
| Revised Cardiac Risk Index for preoperative risk | 2.2 ± 0.7 | 1.2 ± 0.6 | |
| Previous surgery | 31 (57.4%) | 21 (30.5%) | |
| Cirrhosis | 9 (16.7%) | 9 (12.5%) | 0.34 |
| Neoadjuvant systemic therapy | 26 (48.1%) | 12 (16.6%) | |
| High-risk patients | 25 (46.3%) | 16 (22.2%) | |
| High-risk surgical procedures | 15 (27.8%) | 36 (50.0%) | |
| Type of surgical procedure | 0.89 | ||
| Colorectal resection | 7 (12.9%) | 15 (20.8%) | |
| Major hepatectomy w/o hepaticojejunostomy | 7 (12.9%) | 14 (19.4%) | |
| Minor hepatectomy | 12 (22.2%) | 11 (15.2%) | |
| Pancreaticoduodenectomy | 4 (7.4%) | 6 (8.3%) | |
| Distal pancreatectomy | 1 (1.8%) | 0 (0%) | |
| Esophagectomy | 1 (1.8%) | 0 (0%) | |
| Total gastrectomy | 1 (1.8%) | 1 (1.3%) | |
| Distal gastrectomy | 0 (0%) | 2 (2.7%) | |
| Nephrectomy | 3 (5.5%) | 2 (2.7%) | |
| Multivisceral resection | 1 (1.8%) | 2 (2.7%) | |
| Other malignant procedures | 11 (20.3%) | 7 (9.7%) | |
| Orthotopic liver transplantation | 3 (5.5%) | 6 (8.3%) | |
| Kidney transplantation | 3 (5.5%) | 6 (8.3%) | |
| Laparoscopic approach | 17 (31.4%) | 26 (36.1%) | 0.93 |
| Conversion | 1 (1.8%) | 0 (0%) | 0.63 |
| Blood loss (mL) | 165 (62–450) | 400 (100–600) | 0.77 |
| Operative time (min) | 381 (226–488) | 390 (200–400) | 0.12 |
| Patients admitted to the ICU | 20 (37%) | 15 (20.8%) | |
Data expressed as median and interquartile ranges or absolute count and percentages
Bold reflects statistically significant results
ASA American Society of Anesthesiology, ICU intensive care unit